본문 바로가기
KERD
논문KCI 등재

타카야수동맥염의 최신 진료 및 치료 동향

Takayasu Arteritis: Update on Monitoring of Disease Activity and Management

이은영|송영욱|박은혜
대한내과학회 (The Korean Association Of Internal Medicine)|2018.10|대한내과학회지 (The Korean Journal of Medicine)|제93권 제5호|pp. 430-438

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

진단치료타카야수동맥염
주제분류내과학

초록

Takayasu arteritis (TAK) is a chronic inflammatory disease characterized by granulomatous vasculitis of the aorta and its major branches. The rarity of the disease along with its heterogeneous clinical presentation typically lead to late diagnosis and delayed treatment. Furthermore, clinical and serological indices for monitoring disease activity are suboptimal, with no definitive evidence supporting therapeutic approaches in TAK. Nevertheless, there have been recent advances in disease assessment with new scoring systems (Indian Takayasu Arteritis Score), biomarkers including pentraxin 3 and soluble human leukocyte antigen-E, and imaging modalities such as 18F-fluorodeoxyglucose-positron emission tomography. Most of the new information for management of TAK has come from increasing experience with biological agents, such as tumor necrosis factor inhibitors and tocilizumab, used in the treatment of resistant TAK. A number of potential new therapeutic targets that may be useful for the treatment of TAK have been reported, and randomized controlled trials are needed to establish optimal therapeutic approaches.

Abstract

Takayasu arteritis (TAK) is a chronic inflammatory disease characterized by granulomatous vasculitis of the aorta and its major branches. The rarity of the disease along with its heterogeneous clinical presentation typically lead to late diagnosis and delayed treatment. Furthermore, clinical and serological indices for monitoring disease activity are suboptimal, with no definitive evidence supporting therapeutic approaches in TAK. Nevertheless, there have been recent advances in disease assessment with new scoring systems (Indian Takayasu Arteritis Score), biomarkers including pentraxin 3 and soluble human leukocyte antigen-E, and imaging modalities such as 18F-fluorodeoxyglucose-positron emission tomography. Most of the new information for management of TAK has come from increasing experience with biological agents, such as tumor necrosis factor inhibitors and tocilizumab, used in the treatment of resistant TAK. A number of potential new therapeutic targets that may be useful for the treatment of TAK have been reported, and randomized controlled trials are needed to establish optimal therapeutic approaches.

참고문헌 (70)

  1. Kerr GS, "Takayasu arteritis", Ann Intern Med, 120, pp.919~929 (1994)[DOI]
  2. Onen F, "Epidemiology of Takayasu arteritis", Presse Med, 46(7-8), pp.e197~e203 (2017)[DOI]
  3. Mwipatayi BP, "Takayasu arteritis: clinical features and management: report of 272 cases", ANZ J Surg, 75, pp.110~117 (2005)[DOI]
  4. Park MC, "Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification", Scand J Rheumatol, 34, pp.284~292 (2005)[DOI]
  5. Arend WP, "The American college of rheumatology 1990 criteria for the classification of Takayasu arteritis", Arthritis Rheum, 33, pp.1129~1134 (1990)
  6. Jennette JC, "2012 revised international chapel hill consensus conference nomenclature of vasculitides", Arthritis Rheum, 65, pp.1~11 (2013)
  7. Ishikawa K, "Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu's arteriopathy", J Am Coll Cardiol, 12, pp.964~972 (1988)[DOI]
  8. Maksimowicz-McKinnon K, "Takayasu arteritis and giant cell arteritis: a spectrum within the same disease?", Medicine (Baltimore), 88, pp.221~226 (2009)[DOI]
  9. Kim YJ, "Immunoglobulin G4-related disease with lymphoplasmacytic aortitis mimicking Takayasu arteritis", J Clin Rheumatol, 17, pp.451~452 (2011)[DOI]
  10. Craven A, "ACR", EULAR-endorsed study to develop diagnostic and classification criteria for vasculitis (DCVAS), 2013, pp.17, 619~621
  11. Luqmani RA, "Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis", QJM, 87, pp.671~678 (1994)
  12. Quartuccio L, "Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab", Clin Exp Rheumatol, 30, pp.922~928 (2012)
  13. Misra R, "Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010)", Rheumatology (Oxford), 52, pp.1795~1801 (2013)[DOI]
  14. Direskeneli H, "Disease assessment in Takayasu's arteritis", Rheumatology (Oxford), 52, pp.1735~1736 (2013)[DOI]
  15. Lagneau P, "Surgical treatment of Takayasu's disease", Ann Surg, 205, pp.157~166 (1987)[DOI]
  16. Dagna L, "Pentraxin-3 as a marker of disease activity in Takayasu arteritis", Ann Intern Med, 155, pp.425~433 (2011)[DOI]
  17. Carosella ED, "HLA-G and HLA-E: fundamental and Pathophysiological aspects", Immunol Today, 21, pp.532~534 (2000)[DOI]
  18. Goel R, "Soluble-HLA-E: a follow up biomarker in Takayasu arteritis, independent of HLA-E genotype", Int J Rheum Dis, 21, pp.532~540 (2018)[DOI]
  19. Tamura N, "Profiles of serum cytokine levels in Takayasu arteritis patients: potential utility as biomarkers for monitoring disease activity", J Cardiol, 70, pp.278~285 (2017)[DOI]
  20. Hartlage GR, "Multimodality imaging of aortitis", JACC Cardiovasc Imaging, 7, pp.605~619 (2014)[DOI]
  21. Papa M, "Takayasu arteritis: intravascular contrast medium for MR angiography in the evaluation of disease activity", AJR Am J Roentgenol, 198, pp.W279~W284 (2012)[DOI]
  22. Santhosh S, "F-18 FDG PET", CT in the evaluation of Takayasu arteritis: an experience from the tropics, 2014, pp.21, 993~1000
  23. Lee KH, "The role of (18) F-fluorodeoxyglucose-positron emission tomography in the assessment of disease activity in patients with takayasu arteritis", Arthritis Rheum, 64, pp.866~875 (2012)[DOI]
  24. Karapolat I, "Comparison of F18-FDG PET", CT findings with current clinical disease status in patients with Takayasu's arteritis, 2013, pp.31(1 Suppl 75), S15~S21
  25. Cheng Y, "18-FDG-PET in assessing disease activity in Takayasu arteritis: a meta-analysis", Clin Exp Rheumatol, 31(1 Suppl 75), pp.S22~S27 (2013)
  26. Fuchs M, "The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis", Eur J Nucl Med Mol Imaging, 39, pp.344~353 (2012)[DOI]
  27. Mukhtyar C, "EULAR recommendations for the management of primary small and medium vessel vasculitis", Ann Rheum Dis, 68, pp.310~317 (2009)[DOI]
  28. Kotter I, "Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature", Clin Exp Rheumatol, 30(1 Suppl 70), pp.S114~S129 (2012)
  29. Maksimowicz-McKinnon K, "Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients", Arthritis Rheum, 56, pp.1000~1009 (2007)[DOI]
  30. Wen D, "Takayasu arteritis: diagnosis, treatment and prognosis", Int Rev Immunol, 31, pp.462~473 (2012)[DOI]
  31. Hoffman GS, "Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate", Arthritis Rheum, 37, pp.578~582 (1994)[DOI]
  32. Hoffman GS, "Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis", Arthritis Rheum, 50, pp.2296~2304 (2004)[DOI]
  33. Daina E, "Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases", Ann Intern Med, 130, pp.422~426 (1999)[DOI]
  34. de Souza AW, "Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study", Scand J Rheumatol, 41, pp.227~230 (2012)[DOI]
  35. de Souza AW, "Leflunomide in Takayasu arteritis - a long term observational study", Rev Bras Reumatol Engl Ed, 56, pp.371~375 (2016)[DOI]
  36. Wallis RS, "Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab", Semin Arthritis Rheum, 34(5 Suppl1), pp.34~38 (2005)[DOI]
  37. Tripathy NK, "Cytokine mRNA repertoire of peripheral blood mononuclear cells in Takayasu's arteritis", Clin Exp Immunol, 138, pp.369~374 (2004)[DOI]
  38. Tripathy NK, "High TNF-alpha and low IL-2 producing T cells characterize active disease in Takayasu's arteritis", Clin Immunol, 118, pp.154~158 (2006)[DOI]
  39. Molloy ES, "Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up", Ann Rheum Dis, 67, pp.1567~1569 (2008)[DOI]
  40. Schmidt J, "Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup", Arthritis Care Res (Hoboken), 64, pp.1079~1083 (2012)
  41. Mekinian A, "Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study", Rheumatology (Oxford), 51, pp.882~886 (2012)[DOI]
  42. Clifford A, "Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies", Curr Opin Rheumatol, 26, pp.7~15 (2014)[DOI]
  43. Comarmond C, "Anti <TEX>$TNF-{\alpha}$<", TEX> in refractory Takayasu's arteritis: cases series and review of the literature, 2012, pp.11, 678~684
  44. Osman M, "Takayasu's arteritis progression on anti-TNF biologics: a case series", Clin Rheumatol, 30, pp.703~706 (2011)[DOI]
  45. Serra R, "Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis", J Pharmacol Pharmacother, 5, pp.193~196 (2014)[DOI]
  46. Kong X, "The critical role of IL-6 in the pathogenesis of Takayasu arteritis", Clin Exp Rheumatol, 34(3 Suppl 97), pp.S21~S27 (2016)
  47. Saadoun D, "Th1 and Th17 cytokines drive inflammation in Takayasu arteritis", Arthritis Rheumatol, 67, pp.1353~1360 (2015)[DOI]
  48. Goel R, "Rapid control of disease activity by tocilizumab in 10 'difficult-to-treat' cases of Takayasu arteritis", Int J Rheum Dis, 16, pp.754~761 (2013)[DOI]
  49. Bredemeier M, "One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab", Clin Exp Rheumatol, 30(1 Suppl 70), pp.S98~S100 (2012)
  50. Abisror N, "Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review", Autoimmun Rev, 12, pp.1143~1149 (2013)[DOI]
  51. Nakaoka Y, "Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)", Ann Rheum Dis, 77, pp.348~354 (2018)[DOI]
  52. Mekinian A, "Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients", Circulation, 132, pp.1693~1700 (2015)[DOI]
  53. Pazzola G, "Biotherapies in large vessel vasculitis", Rev Med Interne, 37, pp.274~278 (2016)[DOI]
  54. Salvarani C, "Tocilizumab: a novel therapy for patients with large-vessel vasculitis", Rheumatology (Oxford), 51, pp.151~156 (2012)[DOI]
  55. Koster MJ, "Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis", Curr Opin Rheumatol, 28, pp.211~217 (2016)[DOI]
  56. Langford CA, "A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis", Arthritis Rheumatol, 69, pp.846~853 (2017)[DOI]
  57. Hoyer BF, "Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab", Ann Rheum Dis, 71, pp.75~79 (2012)[DOI]
  58. Inder SJ, "Immunophenotypic analysis of the aortic wall in Takayasu's arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions", Cardiovasc Surg, 8, pp.141~148 (2000)[DOI]
  59. Ernst D, "Remission achieved in refractory advanced takayasu arteritis using rituximab", Case Rep Rheumatol, 2012, pp.406963~ (2012)
  60. Caltran E, "Two Takayasu arteritis patients successfully treated with rituximab", Clin Rheumatol, 33, pp.1183~1184 (2014)
  61. Terao C, "Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population", Am J Hum Genet, 93, pp.289~297 (2013)[DOI]
  62. Terao C, "Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application", Scand J Rheumatol, 45, pp.80~82 (2016)[DOI]
  63. Piggott K, "Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis", Circulation, 123, pp.309~318 (2011)[DOI]
  64. Lally L, "Increased rho kinase activity in temporal artery biopsies from patients with giant cell arteritis", Rheumatology (Oxford), 54, pp.554~558 (2015)[DOI]
  65. Saadoun D, "Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience", Circulation, 125, pp.813~819 (2012)[DOI]
  66. Kim YW, "Surgical bypass vs endovascular treatment for patients with supra-aortic arterial occlusive disease due to Takayasu arteritis", J Vasc Surg, 55, pp.693~700 (2012)[DOI]
  67. de Souza AW, "Antiplatelet therapy for the prevention of arterial ischemic events in takayasu arteritis", Circ J, 74, pp.1236~1241 (2010)[DOI]
  68. Kazibudzki M, "New endovascular techniques for treatment of life-threatening Takayasu arteritis", Postepy Kardiol Interwencyjnej, 12, pp.171~174 (2016)
  69. Visona A, "Antithrombotic treatment before and after peripheral artery percutaneous angioplasty", Blood Transfus, 7, pp.18~23 (2009)
  70. Park MC, "Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis", Rheumatology (Oxford), 45, pp.600~605 (2006)[DOI]

이 간행물의 다른 논문 (5건)

임상에서 초음파 급여화의 현황과 대응 방안이혁pp. 413-415한국의 흔한 진드기 매개 감염병: 쯔쯔가무시병과 중증열성혈소판감소증후군김동민, 김다영pp. 416-423새로운 고혈압 가이드라인에 따른 고혈압 진료이해영pp. 447-451개회충증에 의한 호산구성 심근염 1예구자중, 오지홍, 김태형, 윤백현, 김종욱, 이재범, 고두현pp. 482-486강직척추염 발병 이후 전신경화증과 흉수가 동반된 1예송윤아, 이승훈, 김태환, 전재범, 구본산pp. 492-496
원문 보기